-
公开(公告)号：US20090318537A1
公开(公告)日：2009-12-24
申请号：US12505911
申请日：2009-07-20
IPC分类号： A61K31/7105 , C07H21/02
CPC分类号： C12N15/1138 , C12N2310/14
摘要： The present application is directed to siRNA-based silencing of the type II receptor of TGFβ. siRNAs that target this receptor abrogate the receptor protein and transcript, TGFβ-mediated processes such as fibronectin assembly and cell migration also are inhibited and the molecules of the invention are efficacious in reducing the inflammatory response and matrix deposition. These findings show that siRNAs can be successfully delivered both in vitro and in vivo to regulate the TGFβ type II receptor level and modulate wound response. Methods and compositions exploiting the findings of the present invention have a wide-ranging application, extending from treatment of disorders of the eye to other organs and tissues throughout the body.
摘要翻译： 本申请涉及TGFbeta的II型受体的基于siRNA的沉默。 靶向该受体的siRNA消除受体蛋白和转录物，TGFβ介导的过程如纤连蛋白装配和细胞迁移也受到抑制，本发明的分子有效降低炎症反应和基质沉积。 这些研究结果表明siRNA可以在体外和体内成功递送，以调节TGFbeta II型受体水平并调节伤口应答。 利用本发明的发现的方法和组合物具有广泛的应用，从眼睛疾病的治疗延伸到整个身体的其他器官和组织。
-
公开(公告)号：US20060229266A1
公开(公告)日：2006-10-12
申请号：US10567958
申请日：2004-08-10
申请人： Nalin Kumar , Beatrice Yue , Shahid Siddiqui , Asrar Malik , Jose Pulido
发明人： Nalin Kumar , Beatrice Yue , Shahid Siddiqui , Asrar Malik , Jose Pulido
CPC分类号： C12N15/1138 , C12N2310/14
摘要： The present application is directed to siRNA-based silencing of the type II receptor of TGFβ. siRNAs that target this receptor abrogate the receptor protein and transcript, TGFβ-mediated processes such as fibronectin assembly and cell migration also are inhibited and the molecules of the invention are efficacious in reducing the inflammatory response and matrix deposition. These findings show that siRNAs can be successfully delivered both in vitro and in vivo to regulate the TGFβ type II receptor level and modulate wound response. Methods and compositions exploiting the findings of the present invention have a wide-ranging application, extending from treatment of disorders of the eye to other organs and tissues throughout the body.
摘要翻译： 本申请涉及TGFbeta的II型受体的基于siRNA的沉默。 靶向该受体的siRNA消除受体蛋白和转录物，TGFβ介导的过程如纤连蛋白装配和细胞迁移也受到抑制，本发明的分子有效降低炎症反应和基质沉积。 这些研究结果表明siRNA可以在体外和体内成功递送，以调节TGFbeta II型受体水平并调节伤口应答。 利用本发明的发现的方法和组合物具有广泛的应用，从眼睛疾病的治疗延伸到整个身体的其他器官和组织。
-
公开(公告)号：US08067389B2
公开(公告)日：2011-11-29
申请号：US12505911
申请日：2009-07-20
CPC分类号： C12N15/1138 , C12N2310/14
摘要： The present application is directed to siRNA-based silencing of the type II receptor of TGFβ. siRNAs that target this receptor abrogate the receptor protein and transcript, TGFβ-mediated processes such as fibronectin assembly and cell migration also are inhibited and the molecules of the invention are efficacious in reducing the inflammatory response and matrix deposition. These findings show that siRNAs can be successfully delivered both in vitro and in vivo to regulate the TGFβ type II receptor level and modulate wound response. Methods and compositions exploiting the findings of the present invention have a wide-ranging application, extending from treatment of disorders of the eye to other organs and tissues throughout the body.
摘要翻译： 本申请涉及TGF-bgr的II型受体的基于siRNA的沉默。 靶向该受体的siRNA消除受体蛋白和转录物，TGFβb介导的过程如纤连蛋白装配和细胞迁移也受到抑制，本发明的分子有效降低炎症反应和基质沉积。 这些研究结果表明，siRNA可以在体外和体内成功传递，以调节TGF-bgr; II型受体水平和调节伤口反应。 利用本发明的发现的方法和组合物具有广泛的应用，从眼睛疾病的治疗延伸到整个身体的其他器官和组织。
-
-
搜索结果
3 条记录 (耗时 0.011 秒)
